Skip to content

Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum

Effect of Transesophageal Echocardiography-guided Non-fluid Limited Combined Dobutamine Strategy on Hepatic Venous Blood Flow Spectrum in Patients Undergoing Laparoscopic Hepatectomy: a Prospective Randomized Controlled Study

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06210217
Enrollment
51
Registered
2024-01-18
Start date
2024-02-01
Completion date
2024-04-07
Last updated
2024-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Hepatectomy

Brief summary

Patients meeting enrollment criteria will be randomized 1:1 to either the dobutamine or the control group. In the dobutamine group, 3\ 6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. To ensure preload, transesophageal echocardiography (TEE) will be used to monitor left ventricular end-diastolic volume (LVEDV) and stroke volume (SV). In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed, and the liquid will be restricted according to the currently commonly used principle of low central venous pressure(LCVP), nitroglycerin can be used if necessary.

Detailed description

Patients meeting enrollment criteria will be randomized 1:1 to either the dobutamine or the control group. Dobutamine group: 3\ 6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min. Control group: 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 mL/kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min. Dobutamine and nitroglycerin will be stopped after hemostasis, and the anesthesiologist will supplement the infusion according to his/her experience.

Interventions

DRUGDobutamine hydrochloride, Injectable

In the dobutamine group, 3\ 6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.

DRUG0.9% normal saline

In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.

Sponsors

Sichuan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

There are five groups (Participant, surgeon, anesthesiologist, data collector, outcome evaluator). Participants, surgeons, and outcome evaluators will be unaware of the grouping. Blinding will be maintained until data analysis is completed.

Intervention model description

In the dobutamine group, TEE will guide fluid rehydration to ensure preload, and dobutamine will be injected intravenously. In the control group, fluid will be limited by the principle of LCVP and the same amount of normal saline will be injected intravenously.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* undergo laparoscopic partial liver resection at West China Hospital from February 2024 to April 2024 * aged 18 to 65 years * BMI\<30kg/m2 * liver function Child-pugh grade A to B * American Society of Anesthesiologists(ASA)grade Ⅰto Ⅲ.

Exclusion criteria

* coronary heart disease * heart valvular disease * arrhythmia * stroke history * cirrhosis * esophageal varices * esophageal disease, stomach disease, previous esophageal or gastric surgery history * chronic kidney disease * coagulation dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
Variation of hepatic venous blood flow spectrumIntraoperative (after anesthesia induction, 10 minutes after the administration of dobutamine/normal saline, after pneumoperitoneum is established, and after hemostasis is completed.)The method of TEE monitoring hepatic vein blood flow: The TEE probe will be inserted into the patient's esophagus near the gastric fundus to show the liver. Next the probe will be rotated to the right to show the short axis of the inferior vena cava and the hepatic vein. Then the probe angle will be adjusted to 30-40° to show the long axis of the inferior vena cava and the hepatic vein, and the junction of the inferior vena cava and the hepatic vein. To record the blood flow spectrum of the hepatic vein using pulsed Doppler ultrasound (PW mode), the sampling volume should be placed in the hepatic vein, approximately 1.5-2cm away from the inferior vena cava opening. The angle between the sound beam and the blood flow direction should be less than 30°. The blood flow spectrum variation refers to the spectrum change measured at each time point relative to the basic spectrum after anesthesia induction.

Secondary

MeasureTime frameDescription
Loss of albuminPreoperative and the third day after surgery.Preoperative albumin content minus the albumin content on the third day after surgery equals albumin loss.
Surgical field gradeIntraoperative (When the liver parenchyma is transected after the pringle maneuver.)Grade Ⅰ is defined as the inferior vena cava and hepatic veins are very relaxed, and the liver section has little blood seepage, which is very easy to operate. Grade Ⅱ is defined as the inferior vena cava and hepatic vein are relaxed, and the liver section has less blood seepage, which is easy to operate. Grade Ⅲ is defined as the inferior vena cava and hepatic vein are tense, and the liver section oozes more blood, which is difficult to operate. Grade Ⅳ is defined as the inferior vena cava and hepatic vein are obviously tense, and the liver section oozes a lot of blood, which is very difficult to operate.
The remedy rateIntraoperative (The liver parenchyma is transected until hemostasis is completed.)During hepatic parenchyma dissection, if the operating field grade is greater than grade II, the dobutamine dose (3-6 μg/kg/min) will be increased in the dobutamine group, and nitroglycerin (0.3-0.8μg /kg/min) will be added in the control group.
Duration of intraoperative hypotensionIntraoperative (From anesthesia induction to the patient leaving the operating room.)Intraoperative hypotension is defined as SBP\<90mmHg, or MAP\<60mmHg, or MAP/SBP decreasing greater than 20% of the baseline value during the perioperative period.
Ejection fractionIntraoperative (anesthesia induction, 10 minutes after the administration of dobutamine/normal saline, after pneumoperitoneum is established, and after hemostasis is completed.)The ejection fraction will be measured by M-mode ultrasonography on the transgastric short-axis section of the left ventricle using TEE, recording the average value of three cardiac cycles.
The dose of vasoactive drugsIntraoperative (From anesthesia induction to the patient leaving the operating room.)When perioperative SBP\<90mmHg or MAP\< 65mmHg, vasoactive drugs will be administered by the anesthesiologist.
Intraoperative urine volumeIntraoperative (anesthesia induction to the patient leaving the operating room.)After anesthesia induction, all patients will undergo catheterization to record urine volume during the operation.
Intraoperative blood lossintraoperative (Operation starts until hemostasis is completed.)Intraoperative blood loss can be calculated by adding the blood volume absorbed by gauze (8ml for small gauze, 25ml for medium gauze, and 50ml for large gauze) to the blood volume collected in the suction tank during the operation.
Length of operationIntraoperative (From the beginning to the end of the surgery.)From the beginning to the end of the surgery.
Loss of hemoglobinPreoperative and the third day after surgery.Preoperative hemoglobin content minus the hemoglobin content on the third day after surgery equals hemoglobin loss.
Postoperative liver function (TB, ALT, AST) levelsThe first and third day after surgery.The liver function (TB, ALT, AST) levels after surgery.
Incidence of AKIWithin 3 days after surgeryAKI stage 1 is defined as serum creatinine(SCR) increases 1.5-2 times higher than the baseline. AKI stage 2 is defined as SCR is 2-3 times higher than the baseline. AKI stage 3 is defined as SCR increases by more than 3 times compared with the baseline.
Incidence of postoperative pulmonary complicationsUp to 7days after surgery.Pulmonary complications include pulmonary infection, respiratory failure, and moderate or large pleural effusion.
Length of postoperative hospitalizationUp to 2 weeks after surgery.determined by the number of days from operation to discharge.
Lactic acidIntraoperative (after anesthesia induction, liver parenchyma transection is completed.)Invasive blood pressure will be monitored by the radial artery after anesthesia induction, and blood gas analysis will be performed after anesthesia induction and hepatic parenchyma dissection.

Countries

China

Contacts

Primary ContactPeng Liang, Ph.D.
liangpengwch@scu.edu.cn18980602201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026